{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T05:13:39Z","timestamp":1789190019517,"version":"build-2803163510"},"reference-count":26,"publisher":"SAGE Publications","license":[{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Ther Adv Neurol Disord"],"published-print":{"date-parts":[[2024,1]]},"abstract":"<jats:sec><jats:title>Background:<\/jats:title><jats:p> Myelin oligodendrocyte glycoprotein (MOG) IgG related optic neuritis (ON) which manifests as recurrent episodes and severe visual impairment remains a challenging issue in relapse prevention. Tocilizumab (TCZ), a human monoclonal antibody against IL-6R, may be an alternative treatment for the prevention of relapse in refractory MOG-ON patients. <\/jats:p><\/jats:sec><jats:sec><jats:title>Objectives:<\/jats:title><jats:p> To investigate the efficacy and safety of Tocilizumab (TCZ) in patients with recurrent myelin oligodendrocyte glycoprotein IgG related optic neuritis (MOG-ON). <\/jats:p><\/jats:sec><jats:sec><jats:title>Design:<\/jats:title><jats:p> We conducted an open-label, single-arm, nonrandomized, uncontrolled clinical trial at a tertiary neuro-ophthalmology center between April 1, 2021, and April 1, 2022. <\/jats:p><\/jats:sec><jats:sec><jats:title>Methods:<\/jats:title><jats:p> Participants with relapsed MOG-ON, whose disease had been resistant to previous immunotherapies, received tocilizumab as monotherapy or as an add-on therapy and were followed up for at least 12\u2009months. Annual recurrence rate (ARR), best corrected visual acuity (BCVA), and adverse events were recorded for analyses. <\/jats:p><\/jats:sec><jats:sec><jats:title>Result:<\/jats:title><jats:p> Ten patients (7 females and 3 males) with relapsed MOG-ON were included with a mean (SD) ages of 28.6 (20.5) years old at disease onset and 30.9 (19.7) years at first TCZ administration, with a mean disease duration of 26.6 (11.3) months. Seven (70%) patients remained relapse-free, and the median (range) ARR dropped significantly from 1.9 (0.4\u20133.5) to 0.0 (0\u20134.0) during TCZ treatment ( p\u2009=\u20090.006). Three patients experienced a relapse of ON at 2, 3, and 7\u2009months after TCZ therapy. The median BCVA improved from 2.7 (2.0\u20133.0) logMAR at the nadir to 0.2 (0\u20132.0) logMAR at the last follow-up. Adverse effects included transient diarrhea ( n\u2009=\u20091) and upper respiratory infection ( n\u2009=\u20091). <\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion:<\/jats:title><jats:p> This study supports that Tocilizumab therapy, with or without concomitant immunosuppression, is safe and effective in reducing relapses in MOG-ON patients who have failed immunosuppressive therapy or targeted B-cell therapy. <\/jats:p><\/jats:sec><jats:sec><jats:title>Trial registration:<\/jats:title><jats:p> This trial is registered with the Chinese Clinical Trial Registry, number ChiCTR2100045273. (URL: https:\/\/www.chictr.org.cn\/showproj.html?proj=124810 ) <\/jats:p><\/jats:sec>","DOI":"10.1177\/17562864241306685","type":"journal-article","created":{"date-parts":[[2024,12,17]],"date-time":"2024-12-17T04:49:23Z","timestamp":1734410963000},"update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":3,"title":["Efficacy and safety of tocilizumab treatment in refractory MOG-IgG related optic neuritis"],"prefix":"10.1177","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5705-7524","authenticated-orcid":false,"given":"Xintong","family":"Xu","sequence":"first","affiliation":[{"name":"Medical School of Chinese PLA, Beijing, China"},{"name":"Department of Ophthalmology, The Third Medical Center of Chinese PLA General Hospital, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuhang","family":"Wang","sequence":"additional","affiliation":[{"name":"Medical School of Chinese PLA, Beijing, China"},{"name":"Department of Ophthalmology, The Third Medical Center of Chinese PLA General Hospital, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingming","family":"Sun","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, The Third Medical Center of Chinese PLA General Hospital, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuyu","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, The Third Medical Center of Chinese PLA General Hospital, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Biyue","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, The Third Medical Center of Chinese PLA General Hospital, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiyun","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, The Third Medical Center of Chinese PLA General Hospital, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Quangang","family":"Xu","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, The Third Medical Center of Chinese PLA General Hospital, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2910-0446","authenticated-orcid":false,"given":"Shihui","family":"Wei","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, The Third Medical Center of Chinese PLA General Hospital, No. 28 Fuxing Road, Beijing 100853, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huanfen","family":"Zhou","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, The Third Medical Center of Chinese PLA General Hospital, No. 28 Fuxing Road, Beijing 100853, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2024,12,16]]},"reference":[{"key":"bibr1-17562864241306685","doi-asserted-by":"publisher","DOI":"10.1055\/s-0037-1604404"},{"key":"bibr2-17562864241306685","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(21)00218-0"},{"key":"bibr3-17562864241306685","doi-asserted-by":"publisher","DOI":"10.1186\/s12883-022-02848-2"},{"key":"bibr4-17562864241306685","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(13)70259-X"},{"key":"bibr5-17562864241306685","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(19)30488-0"},{"key":"bibr6-17562864241306685","doi-asserted-by":"publisher","DOI":"10.1186\/s12974-016-0718-0"},{"key":"bibr7-17562864241306685","doi-asserted-by":"publisher","DOI":"10.1002\/ana.25648"},{"key":"bibr8-17562864241306685","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuint.2018.10.012"},{"key":"bibr9-17562864241306685","doi-asserted-by":"publisher","DOI":"10.1016\/j.ncl.2020.09.003"},{"key":"bibr10-17562864241306685","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000001076"},{"key":"bibr11-17562864241306685","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2015.0533"},{"key":"bibr12-17562864241306685","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-022-11364-9"},{"key":"bibr13-17562864241306685","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(13)70076-0"},{"key":"bibr14-17562864241306685","doi-asserted-by":"publisher","DOI":"10.1007\/s10072-022-06495-w"},{"key":"bibr15-17562864241306685","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2020.102166"},{"key":"bibr16-17562864241306685","doi-asserted-by":"publisher","DOI":"10.2174\/18756190MTA2cMjAm1"},{"key":"bibr17-17562864241306685","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp-2018-317969"},{"key":"bibr18-17562864241306685","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2020.102483"},{"key":"bibr19-17562864241306685","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000200150"},{"key":"bibr20-17562864241306685","doi-asserted-by":"publisher","DOI":"10.1001\/archopht.1991.01080120057025"},{"key":"bibr21-17562864241306685","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000001100"},{"key":"bibr22-17562864241306685","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2019.2940"},{"key":"bibr23-17562864241306685","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000000841"},{"key":"bibr24-17562864241306685","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awaa102"},{"key":"bibr25-17562864241306685","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000000101"},{"key":"bibr26-17562864241306685","doi-asserted-by":"publisher","DOI":"10.1016\/j.jneuroim.2020.577361"}],"container-title":["Therapeutic Advances in Neurological Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/17562864241306685","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/17562864241306685","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/17562864241306685","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,3]],"date-time":"2025-03-03T12:14:53Z","timestamp":1741004093000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/17562864241306685"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1]]},"references-count":26,"alternative-id":["10.1177\/17562864241306685"],"URL":"https:\/\/doi.org\/10.1177\/17562864241306685","relation":{},"ISSN":["1756-2864","1756-2864"],"issn-type":[{"value":"1756-2864","type":"print"},{"value":"1756-2864","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,1]]},"article-number":"17562864241306685"}}